安罗替尼治疗晚期胰腺癌疗效观察

目的探讨安罗替尼在晚期胰腺癌治疗中的疗效及不良反应。方法选取2018年9月～2019年5月在我院经病理组织学检查确诊的晚期胰腺癌患者10例,经过至少1个方案化疗后,给予安罗替尼进行二线或二线以上治疗。开始治疗时患者均给予安罗替尼12 mg,口服,1次/d,连续服用14 d,停用1周,每21天重复,直至疾病进展或减量后仍不能耐受不良反应为止。每6周复查CT或MRI评价疗效,若不良反应达3级或4级,安罗替尼剂量降为10 mg/d或8 mg/d。结果疗效评价结果显示,PR 1例,SD 3例,PD 6例,ORR为10.0%、DCR为40.0%,PD占60.0%,PFS为2.3个月(95%CI:1.6～2.9)。不良反应主要为疲劳、食欲减退、头痛和高血压,其中1例减量至8 mg/d,2例减量至10 mg/d。结论安罗替尼对晚期胰腺癌有效,不良反应可以耐受。

Efficacy of anlotinib in the treatment of advanced pancreatic cancer

Objective To observe the efficacy and adverse reactions of anlotinib in the treatment of advanced pancreatic cancer.Methods Ten patients with advanced pancreatic cancer diagnosed by histopathology in our hospital from September 2018 to May 2019 were selected and given anlotinib for second-or second-line therapy after at least one regimen of chemotherapy.At the beginning of the treatment,all patients were given anlotinib 12 mg,once a day for 14 days,discontinued for 1 week,repeated every 21 days until the disease progressed or they were still unable to tolerate adverse reactions after the reduction.The therapy effect was evaluated by CT or MRI every 6 weeks.If the adverse reaction reached grade 3 or grade 4,the dose of anlotinib was reduced to 10 mg/d or 8 mg/d.Results For the therapy effect,there was 1 case of PR,3 cases of SD,6 cases of PD,ORR was 10.0%,DCR was 40.0%,PD was 60.0%,and 2.3 months of PFS(95%CI:1.6-2.9).The main adverse reactions were fatigue,loss of appetite,headache and high blood pressure.One case reduced to 8 mg/d,and 2 cases reduced to 10 mg/d.Conclusion Anlotinib is effective for advanced pancreatic cancer and its adverse reactions can be tolerated.